Noven garners $25M payday on sales milestone
Noven will pocket the second of three potential $25 million milestones outlined in its deal with Shire. Shire says that the ADHD drug Daytrana continues to rack up enough market share to trigger the payments, exceeding $50 million in revenue for the 12 months ended on June 30. Noven will get its third big milestone payment if Daytrana breaks the $75 million mark.
- check out the release
- here's the report from Tech Journal South
Related Articles:
Noven expands pipeline with $125M JDS buyout. Report
FDA rejects Noven's copycat version of Duragesic pain patch. Report
FDA approves Daytrana ADHD patch. Report
Be the first to comment
More stories about FDA Generics Deals milestones pipeline Shire competitors ADHD Biotech company news
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
